GENENTA SCIENCE
Genenta Science is a biotechnology company that develops gene transfer therapy for the treatment of cancer tumors. The company is based in Milan, Italy.
GENENTA SCIENCE
Industry:
Biotechnology Clinical Trials Genetics Health Care
Founded:
2014-01-01
Address:
Milano, Lombardia, Italy
Country:
Italy
Website Url:
http://www.genenta.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
33.94 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Qianzhang Investment
Qianzhang Investment investment in Series C - Genenta Science
Club degli Investitori
Club degli Investitori investment in Series C - Genenta Science
Club degli Investitori
Club degli Investitori investment in Series B - Genenta Science
Mediobanca Banca di Credito Finanziario S.p.A.
Mediobanca Banca di Credito Finanziario S.p.A. investment in Series A - Genenta Science
Official Site Inspections
http://www.genenta.com Semrush global rank: 4.92 M Semrush visits lastest month: 1.75 K
- Host name: calvin.dnshigh.com
- IP address: 86.107.36.46
- Location: Voineasa Romania
- Latitude: 45.4167
- Longitude: 23.95
- Timezone: Europe/Bucharest
- Postal: 247750
More informations about "Genenta Science" on Search Engine
Genenta Science - Crunchbase Company Profile & Funding
About. Genenta Science is a biotechnology company that develops gene transfer therapy for the treatment of cancer tumors. Milano, Lombardia, Italy. 1-10. Post-IPO Secondary. …See details»
Genenta Science | LinkedIn
Genenta (Nasdaq: GNTA) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell therapy for the treatment of a …See details»
Genenta Science | LinkedIn
Genenta Science | 6,773 followers on LinkedIn. Permanent Self-Vaccination Against Cancer | Genenta (Nasdaq: GNTA) is a clinical-stage biotechnology company engaged …See details»
Genenta Science and AGC Biologics Enter Development and …
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic …See details»
Press Releases | Genenta Science
Press Releases. Year. None. Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid …See details»
Genenta Science: Advancing Cancer Immunogene Therapies
Nov 22, 2021 den-belitsky/iStock via Getty Images. About. Genenta Science S.p.A. ( NASDAQ: GNTA) is an Italy based clinical stage biotechnology company, spun-off in …See details»
Genenta Platform | Genenta science
Cell-based platform for safe tumor treatments. Our proprietary platform centers on a transgene expression control vector that provides dual control at the transcriptional and …See details»
Corporate Governance | Genenta Science
Corporate Governance Overview. The Board of Directors of Genenta Science (the "Company") sets high standards for the Company's employees, officers and directors. …See details»
Genenta Science - Funding, Financials, Valuation & Investors
Genenta Science is registered under the ticker NASDAQ:GNTA . Their stock opened with $11.50 in its Dec 15, 2021 IPO. Genenta Science is funded by 5 investors. Growth …See details»
Genenta Science and AGC Biologics Enter Development and …
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic …See details»
Board of Directors Demo | Genenta science
CEO Chairman Co-founder. Pierluigi Paracchi is an experienced venture capital investor, Founder and CEO of Quantica SGR, Co-founder of Axòn Capital and AurorA Science …See details»
Genenta Science S.p.A. (GNTA) - Yahoo Finance
Genenta Science S.p.A. (GNTA) NasdaqCM - NasdaqCM Delayed Price. Currency in USD. Follow. 2W 10W 9M. 3.4661 +0.0161 (+0.47%) At close: 04:00PM EDT. 1d. 5d.See details»
Genenta Science S.p.A. (GNTA) - Stock Analysis
4 days ago Genenta to Present at Upcoming Scientific and Investor Conferences. MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. …See details»
SEC Filing | Genenta Science
GENENTA SCIENCE S.P.A. (Exact name of Registrant as specified in its charter) ... Italy : Not Applicable (State or other jurisdiction of. incorporation or organization) (I.R.S. …See details»
Investor Relations | Genenta Science
Oct 2, 2023 See details. New Corporate Deck - October 2023. Title: Genenta Corporate Presentation. Time: October 2, 2023. Innovit road to JPM’24. Date: October 25, 2023. …See details»
Genenta Science. Information about the issuer. (LEI ...
Organization: Genenta Science LEI 815600E860D130824E49, SWIFT GNSCITM2XXX ... Genenta Science SPA operates as a clinical-stage biotechnology company. The …See details»
Understanding the Lifecycle of Flaky Tests and Identifying Flaky ...
1 day ago First, we focus on predicting the lifetime of a flaky test, an issue that has been left unaddressed in the flaky tests research area. Secondly, we question the efficiency of …See details»